Simcha Therapeutics
About
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Overview
Pipeline
Patients
Culture & Careers
News
Press Releases
Media
Publications
Contact
ASH22 could be IL-18’s watershed moment
Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise
Engineering a better immunotherapy to outwit cancer — and launch a biotech
Simcha debuts with $25M to advance custom-built IL-18 for cancer
MENU
About
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Overview
Pipeline
Patients
Culture & Careers
News
Press Releases
Media
Publications
Contact